DBV Technologies S.A. (DBVT)
NASDAQ: DBVT · Real-Time Price · USD
23.77
-0.67 (-2.74%)
At close: Jan 28, 2026, 4:00 PM EST
23.77
0.00 (0.00%)
After-hours: Jan 28, 2026, 4:00 PM EST
DBV Technologies Revenue
Revenue (ttm)
$5.50M
Revenue Growth
-56.04%
P/S Ratio
263.53
Revenue / Employee
$47,026
Employees
117
Market Cap
1.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 16.71M | 2.42M | 16.90% |
| Dec 31, 2017 | 14.29M | 4.73M | 49.50% |
| Dec 31, 2016 | 9.56M | 2.86M | 42.76% |
| Dec 31, 2015 | 6.70M | 933.42K | 16.20% |
| Dec 31, 2014 | 5.76M | 500.37K | 9.51% |
| Dec 31, 2013 | 5.26M | 1.60M | 43.65% |
| Dec 31, 2012 | 3.66M | 1.24M | 51.01% |
| Dec 31, 2011 | 2.43M | 143.69K | 6.30% |
| Dec 31, 2010 | 2.28M | 734.19K | 47.44% |
| Dec 31, 2009 | 1.55M | 93.10K | 6.40% |
| Dec 31, 2008 | 1.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Innoviva | 388.52M |
| Pharming Group | 362.27M |
| AnaptysBio | 169.47M |
| Immatics | 99.45M |
| EyePoint | 42.34M |
| Inventiva | 19.93M |
| Relay Therapeutics | 8.36M |
| AtaiBeckley | 3.02M |
DBVT News
- 11 days ago - DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing - GlobeNewsWire
- 16 days ago - Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025 - GlobeNewsWire
- 23 days ago - Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025 - GlobeNewsWire
- 6 weeks ago - Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing - Benzinga
- 6 weeks ago - DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children Transcript - Seeking Alpha
- 2 months ago - DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years - GlobeNewsWire
- 3 months ago - DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - GlobeNewsWire
- 3 months ago - DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer - GlobeNewsWire